Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

NCT01150890 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
130
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups

Conditions

Interventions

Sponsor

Amgen